RSS

liver cancer

Singapore-based biotech company, Lion TCR, has received approval from the Health Services Authority (HSA) of Singapore for its Phase I/II multicentre clinical study of its T cell engineered immunotherapy for the treatment of liver cancer. more

News

Taiwanese biopharma company, OBI Pharma, has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation for its treatment of hepatocellular carcinoma (HCC), OBI-3424. more

News

Clinical-stage biotech company, Genoscience Pharma, has started administering GNS561 in a Phase I/IIa trial of patients with advanced liver cancer. more

News

Global research and development-based pharmaceutical company, Eisai, has submitted a marketing authorization application to the European Medicines Agency (EMA) for its first-line hepatocellular carcinoma treatment, lenvatinib. more

News

Researchers at the University of Huddersfield have developed a new lab technique that could potentially aid the development and success rate of an important anti-cancer treatment. more

News

Late clinical-stage nanomedicine company Nanobiotix has been authorised to begin a new clinical trial in liver cancers for its lead NanoXray product, NBTXR3. more

News